A late phase II study of S-1 for metastatic pancreatic cancer

Okusaka, Takuji; Funakoshi, Akihiro; Furuse, Junji; Boku, Narikazu; Yamao, Kenji; Ohkawa, Shinichi; Saitô, Hiroshi

doi:10.1007/s00280-007-0514-8

Cited by 155 publications

(101 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11) We selected S-1, another active drug in Asian countries including Japan, for pancreatic cancer. S-1 showed noninferiority to gemcitabine in Japanese large-scale trials, 12,13) and we also previously reported that S-1 improved the survival time of patients with unresectable pancreatic cancer. 14,15) Mycophenolate mofetile was discontinued because both mycophenolate mofetile and S-1 combination share the characteristics of DNA synthesis inhibition and simultaneous administration of the two drugs may increase the risk of myelosuppression.…”

Section: Discussionsupporting

confidence: 52%

A Case of Pancreatic Cancer After Heart Transplantation

et al. 2012

View full text Add to dashboard Cite

SummaryMalignancy is not uncommon with immunosuppressive therapy, but pancreatic cancer is infrequently complicated in recipients of heart transplantation. Here we report a transplant case diagnosed with pancreatic cancer 4 years and 8 months after the heart transplantation. We changed the immunosuppressive regimen after the malignancy was detected, and administered everolimus along with chemotherapy using S-1, an oral fluoropyrimidine prodrug. The patient lived for 8 months after the diagnosis, and received metallic stenting for the biliary and duodenal obstruction. Also, to the best of our knowledge, this is the first report about chemotherapy and endoscopic intervention for pancreatic cancer in a heart transplantation patient. (Int Heart J 2012; 53: 205-207)

show abstract

Section: Discussionsupporting

confidence: 52%

A Case of Pancreatic Cancer After Heart Transplantation

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[9][10][11] Furthermore, S-1 has been also identified as an effective agent for the treatment of colorectal, 12 head and neck, 13 breast, 14 non-small-cell lung, 15 biliary tract 16 and pancreatic cancers. 17 5-FU is not used in patients with prostate cancer because of its poor efficacy and severe side effects. [18][19][20] The therapeutic effect of S-1 for treating prostate cancer is still not fully understood.…”

Section: Introductionmentioning

confidence: 99%

Low‐dose docetaxel enhances the sensitivity of S‐1 in a xenograft model of human castration resistant prostate cancer

Hasegawa¹,

Miyajima²,

Kosaka³

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

S-1 is a recently developed dihydropyrimidine dehydrogenase inhibitor fluoropyrimidine and has demonstrated high maximum plasma 5-Fluorouracil (5-FU) levels with mild toxicity, and an oral formulation has resulted in an improvement in patient quality of life. The aims of the present study were to determine the efficacy of S-1 or S-1 combined with docetaxel (DOC) using castration resistant prostate cancer (CRPC) cells and to explore their clinical potential for treating CRPC patients. LNCaP cells, androgen dependent prostate cancer (ADPC) cells and C4-2 cells, which are a CRPC subline of LNCaP cells, were used. Specimens obtained from ADPC and CRPC patients were also evaluated. The CRPC specimens and C4-2 cells exhibited significantly lower thymidylate synthase (TS) expression, a target of 5-FU, than the ADPC specimens and LNCaP cells. In vitro, C4-2 cells exhibited higher sensitivity to 5-FU than LNCaP cells. In C4-2 xenograft model, S-1 monotherapy suppressed tumor growth and low-dose DOC enhanced the anti-tumor effect of S-1. In vitro, low-dose DOC, which did not induce G2/M arrest, increased p53 and p21 and resulted in down-regulation of TS in C4-2 cells, and down-regulation of TS is considered to be responsible for the synergistic effect of S-1 in vivo. The present findings indicate that CRPC patients with androgen ablation may be good candidates for 5-FU based chemotherapy, and these regimens have attractive therapeutic potential for clinical practice, and they may have a significant impact on therapeutic options.

show abstract

“…During the past decade, several phase II studies demonstrated the efficacy of S-1 in major solid cancers. Response rates of S-1 were 45.0% in gastric cancer [6,7], 32.6% in colorectal cancer [8,9], 18.2% in lung cancer [10,11], 41.7% in breast cancer [12], and 32.2% in pancreatic cancer [13,14]. In addition, the response rate of S-1 was 34.1% in head and neck cancer [15,16].…”

Section: Introductionmentioning

confidence: 99%

S-1 Salvage Chemotherapy for Esophageal Squamous Cell Carcinoma Refractory to the Standard Chemotherapy

Tamaoki¹,

Ezoe²,

Aoyama³

et al. 2017

J Cancer Sci Ther

View full text Add to dashboard Cite

Objective: Fluorouracil, cisplatin, and taxane are widely used in the standard chemotherapy regimens for esophageal squamous cell carcinoma (ESCC). Although S-1 is expected to demonstrate considerable efficacy for ESCC, there is any clinical data. The purpose of this retrospective study was to evaluate the efficacy and safety of S-1 as salvage chemotherapy for ESCC.Methods: From 2007 to 2014, fifteen patients with ESCC refractory or refusal to the standard chemotherapy were treated with S-1 as salvage treatment at the Kyoto University Hospital and their clinical records were reviewed retrospectively. Results:The median age was 70 years old (range: 63-77). A complete response (CR) was achieved in 1 case (7%). A stable disease (SD) and progressive disease (PD) were seen in 9 (60%) and 5 (33%) cases, respectively. After a follow-up duration of 13.9 months, median progression free survival and overall survival was 6.2 and 10.0 months, respectively. One-year survival rate was 33.3%. Toxicities greater than CTCAE grade 3 were observed in 3 of 15 patients (20%). Two patients had grade 3 neutropenia and one patient had grade 3 diarrhea. There was no treatment related death.Conclusions: S-1 salvage chemotherapy could be expected to be an effective and safe treatment option to improve the prognosis of patients with ESCC refractory to the standard chemotherapy.

show abstract

A late phase II study of S-1 for metastatic pancreatic cancer

Cited by 155 publications

References 23 publications

A Case of Pancreatic Cancer After Heart Transplantation

A Case of Pancreatic Cancer After Heart Transplantation

Low‐dose docetaxel enhances the sensitivity of S‐1 in a xenograft model of human castration resistant prostate cancer

S-1 Salvage Chemotherapy for Esophageal Squamous Cell Carcinoma Refractory to the Standard Chemotherapy

Contact Info

Product

Resources

About